Small-cap healthcare and emerging growth stocks continue to generate investor interest as multiple companies announced ...
Stocktwits on MSN
NEONC receives FDA written feedback on NEO212 CMC development and capsule-to-tablet transition
FDA feedback provides detailed manufacturing and formulation requirements for continued late-stage development of NEO212CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings ...
NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. This should not be construed as financial or investment advice. Trading involves ...
Its critical data efforts received a significant boost after the company announced that the Department of Health – Abu Dhabi granted Investigational New Drug (IND) authorization for NEO212, NeOnc's ...
Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol-temozolomide conjugate, in the United Arab Emirates Follows completion of Phase 1 dose escalation and selection of ...
Volatile Organic Compounds (VOCs), including terpenes, aldehydes, alcohols, esters, and ketones, are essential for the characteristic aroma and flavour of fruits and flowers. These compounds, which ...
NEO100-01, an intranasal perillyl alcohol therapy, targets IDH1-mutant astrocytomas, aiming to bypass the blood-brain barrier. The phase 2a trial is nearing full enrollment, conducted at seven U.S.
The FDA's designation for NEO100 highlights the urgent need for treatments for pediatric-type diffuse high-grade gliomas, a rare and aggressive brain cancer. NeOnc Technologies may receive a Rare ...
The system delivers NEO100, an ultra-purified form of perillyl alcohol, through inhalation. The molecule enters the cerebrospinal fluid via the olfactory nerve, ensuring direct contact with tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results